DUBLIN--(BUSINESS WIRE)--The "Endometriosis - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.
Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report analyzes the worldwide markets for Endometriosis in US$ Million.
The report profiles 38 companies including many key and niche players such as:
- AbbVie Inc. (US)
- AEterna Zentaris Inc. (Canada)
- Astellas Pharma Inc. (Japan)
- AstraZeneca Plc. (UK)
- Bayer HealthCare Pharmaceuticals, Inc. (US)
- Debiopharm Group (Switzerland)
- Evotec AG (Germany)
- Kissei Pharmaceutical Co., Ltd. (Japan)
- Neurocrine Biosciences, Inc. (US)
- ObsEva SA (Switzerland)
- Pfizer, Inc. (US)
- Repros Therapeutics, Inc. (US)
- Roivant Sciences Ltd. (US)
- Takeda Pharmaceutical Company Limited (Japan)
- ValiRx Plc (UK)
Key Topics Covered:
I. Introduction, Methodology & Product Definitions
II. Executive Summary
1. Industry Overview
2. Endometriosis & Its Treatment - An Overview
3. Treatment of Endometriosis
4. Select Clinical Trials/Product Innovations & Approvals
5. Recent Industry Activity
6. Focus on Select Global Players
7. Global Market Perspective
Total Companies Profiled: 38 (including Divisions/Subsidiaries 40)
The United States (11)
Canada (3)
Japan (6)
Europe (15)
- France (1)
- Germany (3)
- The United Kingdom (2)
- Rest of Europe (9)
Asia-Pacific (Excluding Japan) (3)
Middle East (1)
Latin America (1)
For more information about this report visit https://www.researchandmarkets.com/research/s3q38f/global?w=4
